Clinical Trial Update: Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin [Phase 1]

View source ↗

Summary

Phase 1 trial update of Gemcitabine in combination with TheraSphere Y-90 for hepatic tumors of pancreatobiliary origin. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: Emory University | Conditions: Pancreatic Neoplasms, Cholangiocarcinoma | Phase 1 | Status: TERMINATED